Table 1.
Time (min) | Nonspecific siRNA | TLR2 siRNA | TLR4 siRNA |
---|---|---|---|
120 | 2.88 ± 0.93 | 1.75 ± 0.25 | 1.50 ± 0.71 |
150 | 12.00 ± 1.96 | 10.50 ± 1.15 | 9.88 ± 1.89 |
180 | 15.75 ± 1.85 | 18.00 ± 1.12 | 17.00 ± 2.73 |
210 | 20.13 ± 2.08 | 20.40 ± 1.74 | 22.10 ± 2.37 |
240 | 21.38 ± 1.93 | 21.90 ± 1.26 | 25.00 ± 2.76 |
270 | 22.88 ± 1.59 | 21.80 ± 1.70 | 25.60 ± 2.68 |
300 | 23.75 ± 1.81 | 19.90 ± 1.80 | 25.90 ± 2.13a |
330 | 20.25 ± 2.31 | 17.00 ± 1.64 | 23.00 ± 1.79b |
360 | 14.60 ± 2.63 | 11.60 ± 0.68 | 18.20 ± 2.24b |
HDMVECs were placed in the wells of angioslides coated with growth factor–reduced Matrigel after transfection with siRNA to a nonspecific target, TLR2 or TLR4. After allowing the cells to settle for 2 h, tube formation was imaged every 15 min for a total of 360 min. The number of tubes visible in each frame was calculated at 30-min intervals for each treatment group.
p < 0.05;
p < 0.03 TLR4KD cells versus TLR2KD cells. N = 3 experiments.